FinalDoseYC P26 landing page report.
← Back to YC P26

Your landing page’s weakest score is Trust.

Fix Trust

Score over time

6560555045Strand Therapeutics 53 on Apr 23 (Wayback)Strand Therapeutics 55 on Jul 23 (Wayback)Strand Therapeutics 51 on Sep 20 (Live)Senti Biosciences 50 on Apr 15 (Wayback)Senti Biosciences 52 on May 18 (Wayback)Senti Biosciences 50 on Jun 17 (Wayback)Senti Biosciences 48 on Jul 23 (Wayback)Senti Biosciences 51 on Jul 31 (Wayback)Senti Biosciences 51 on Sep 7 (Wayback)Senti Biosciences 48 on Sep 22 (Live)Asher Bio 53 on Apr 23 (Wayback)Asher Bio 52 on May 10 (Wayback)Asher Bio 52 on Jun 16 (Wayback)Asher Bio 52 on Sep 22 (Live)FinalDose 56 on May 12 (Wayback)FinalDose 61 on Sep 20 (Live)May 12Sep 20
Past reportsShow past reportsHide past reports
  1. Sep 20, 202661LiveOverall +5 · CTA +14 · Mobile web +8Viewing
  2. May 12, 202656First tracked report — strongest Information hierarchy 76, weakest Trust 28View →

Trust

30Poor

Proof that the product is real, competent, and safe to try.

Strand Therapeutics
Senti Biosciences
Asher Bio
Trust read
FinalDoseNo visible trust signal identified.
Strand Therapeutics"Strand is a clinical-stage biotechnology company with a pipeline of breakthrough mRNA therapeutics for cancers and auto
Senti Biosciences"Senti Bio is a clinical-stage company developing a new generation of cell and gene therapies" copy on mobile
Asher Bio"Our immunotherapies selectively activate only the immune cell types that drive the desired therapeutic response" — spec

Value props

58Fair

Title, subtitle, hero — do they sell the product's true value?

FinalDose’s headline vagueThe Complete Architecture for Cancer TherapyDNA gives us the address. Programmability gives us the scale. Elimination gives us the cure.

Working

  • Subhead cadence is memorable and bold
  • "Cure" carries strong emotional pull
  • Confident, category-owning tone

Could improve

  • Headline never says what FinalDose is
  • No proof points, data, or numbers
  • Hero image decorates, doesn't demonstrate

CTA

62Fair

Copy, size, verb, cost-feel — does the primary CTA earn the click?

FinalDose

Problems

  • no action verb — reads as a label
  • duplicates the nav 'Whitepaper' link
  • click feels like homework, not value

Mobile web

72Fair

The phone experience as a first-class citizen.

Mobile web annotations on the mobile capture123
  1. Six-line hero headline — Desktop-scale type wraps into six lines, dominating the fold and pushing the CTA down.
  2. 'SIMMERING...' eyebrow label — Cryptic status text occupies the hero's first read without conveying any value.
  3. Whitepaper CTA button — Desktop-proportioned button floats at partial width instead of a thumb-friendly full-bleed bar.

Information hierarchy

82Strong

Does the design help or inhibit what the page is trying to say?

Information hierarchy annotations on the desktop capture123
  1. SIMMERING eyebrow text — Cryptic label with no evident meaning sits first in the scan path and stalls comprehension of the headline.
  2. Nav Whitepaper link — Duplicates the primary CTA at nav weight, splitting the one action across two targets.
  3. Whitepaper CTA button — Label names a document, not an outcome, weakening the single action the hierarchy funnels toward.